India, July 29 -- InSilico Medicine Cayman TopCo (3696.HK), a clinical-stage artificial intelligence-driven drug discovery company, on Wednesday announced that the U.S. FDA has granted Fast Track Designation to ISM6331, a pan-TEAD inhibitor.
The designation was for the treatment of unresectable malignant pleural mesothelioma in patients whose disease has progressed after prior immunotherapy and platinum-based chemotherapy.
Malignant pleural mesothelioma is a rare, aggressive cancer of the lung lining, most often linked to long-term asbestos exposure and associated with limited treatment options and poor survival.
The designation is intended to accelerate the development and regulatory review of therapies for serious conditions with unmet...